Scholar Rock Holding Corp at JPMorgan Healthcare Conference TranscriptJan 09, 2024- Q3 2023 Scholar Rock Holding Corp Earnings Call TranscriptNov 07, 2023$12.35 (+1.48%)Earnings
- Scholar Rock Holding Corp Overview of the Current Treatment Landscape and Unmet Needs of Patients with SMA TranscriptJul 12, 2023
- Scholar Rock Holding Corp at JPMorgan Healthcare Conference TranscriptJan 10, 2023
- Scholar Rock Holding Corp TOPAZ Phase 2 Clinical Trial Data TranscriptJun 17, 2022
- Scholar Rock Holding Corp at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2022
- Scholar Rock Holding Corp at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 09, 2021
- Scholar Rock Holding Corp to Host KOL Discussing Apitegromab's Therapeutic Potential in Patients with SMA Call TranscriptJun 15, 2021
- Scholar Rock Holding Corp at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2021
- Scholar Rock Holding Corp Annual Shareholders Meeting TranscriptMay 27, 2021
- Scholar Rock Holding Corp to Announce the 12-Month Top-line Results of TOPAZ Phase 2 Trial TranscriptApr 06, 2021
- Scholar Rock Holding Corp at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- Scholar Rock Holding Corp to Discuss the SRK-015 TOPAZ Interim Analysis Results Conference Call TranscriptOct 27, 2020
- Scholar Rock Holding Corp at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 16, 2020
- Q2 2020 Scholar Rock Holding Corp Earnings Call TranscriptAug 07, 2020$14.07 (+2.25%)Earnings
- Scholar Rock Holding Corp Annual Shareholders Meeting TranscriptMay 29, 2020
- Scholar Rock Holding Corp at Morgan Stanley Healthcare Conference TranscriptSep 11, 2019
- Scholar Rock Holding Corp at Oppenheimer Healthcare Conference TranscriptMar 19, 2019
- Scholar Rock Holding Corp at Cowen Health Care Conference TranscriptMar 13, 2019
- Scholar Rock Holding Corp SRK-015 Interim Phase 1 Results and Phase 2 Trial Design Conference Call TranscriptFeb 26, 2019
Scholar Rock Holding Corp at JPMorgan Healthcare Conference Transcript
Welcome everyone to the 42nd Annual J.P. Morgan Healthcare Conference. My name is Tessa Romero, and I'm one of the senior biotechnology analysts here at J.P. Morgan. Our next presenting company is Scholar Rock. And speaking, on behalf of the Company, we have CEO, Jay Backstrom. Jay, over to you.
All right. Well, thank you, Tess. Good afternoon, everybody. It's a pleasure to be here representing Scholar Rock at this year's J.P. Morgan Healthcare Conference. And really pleased to have the opportunity to highlight the progress we've made since I joined the company a little over a year ago, and to outline the exciting year that we have ahead.
I will be making forward-looking statements, so I suggest you refer to this slide for my disclaimers. You may also refer to the section entitled risk factors in our quarterly and annual reports.
For those new to Scholar Rock, we are a global leader in harnessing the life-changing potential TGF-beta
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
